RESUMEN
<p><b>OBJECTIVE</b>To investigate the value of technetium-99m methoxyisobutylisonitrile ((99)Tc(m)-MIBI) imaging in predicting the efficacy of neoadjuvant chemotherapy (NCT) and prognosis in patients with operable breast cancer.</p><p><b>METHODS</b>Sixty five patients with breast cancer underwent (99)Tc(m)-MIBI scintimammography before NCT, and static planar images were taken at 10 min and 180 min after scintimammography. The clearance rate was calculated in each patient, correlation between the clearance rate and efficacy of NCT, and the disease free survival rate were analyzed.</p><p><b>RESULTS</b>The mean clearance rate of 65 patients was (17.4 ± 6.8)%. The efficacy of NCT was 86.2% (CR 4 cases, PR 52 cases, SD 8 cases, and PD 1 case), and the mean clearance rate of patients with good response or poor response of chemotherapy were (15.5 ± 5.0)% and (29.2 ± 3.2)%, respectively. There was a significant difference between the two groups. The average disease free survival rate in the group with low clearance rate was (75.8%, P = 0.046), significantly higher than that in the group with high clearance rate (53.1%).</p><p><b>CONCLUSION</b>Scintimammography of (99)Tc(m)-MIBI may be used to evaluate the efficacy and prognosis of NCT for patients with operable breast cancer.</p>
Asunto(s)
Adulto , Anciano , Femenino , Humanos , Persona de Mediana Edad , Protocolos de Quimioterapia Combinada Antineoplásica , Usos Terapéuticos , Neoplasias de la Mama , Diagnóstico por Imagen , Quimioterapia , Carcinoma Ductal de Mama , Diagnóstico por Imagen , Quimioterapia , Carcinoma Lobular , Diagnóstico por Imagen , Quimioterapia , Quimioterapia Adyuvante , Ciclofosfamida , Usos Terapéuticos , Supervivencia sin Enfermedad , Epirrubicina , Usos Terapéuticos , Etopósido , Usos Terapéuticos , Fluorouracilo , Usos Terapéuticos , Estudios de Seguimiento , Terapia Neoadyuvante , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Cintigrafía , Radiofármacos , Inducción de Remisión , Taxoides , Usos Terapéuticos , Tecnecio Tc 99m SestamibiRESUMEN
<p><b>BACKGROUND</b>Keratinocyte serum-free medium (K-SFM) is a defined medium used to support the growth of primary keratinocytes and embryonic stem cell. The aim of this research was to optimize enrichment of breast cancer stem cells (CSCs) using K-SFM.</p><p><b>METHODS</b>A K-SFM was used to enrich CSCs from two breast cancer cell lines and a primary culture of breast cancer. RPMI-1640 supplemented with 10% fetal calf serum (FCS) was used as a control. CSCs were identified with flow cytometry using CD44(+)/CD24(-) as molecular markers. The expression of a variety of CSC markers (Oct-4, ABCG2, Nanog, N-cadherin, and E-cadherin) was analyzed with real-time PCR.</p><p><b>RESULTS</b>Much higher percentage of CSCs was achieved with K-SFM: 17.3% for MCF-7 cells, 17.4% for SKBR-3, and 20.0% for primary breast cancer culture. Less than 1% CSC was achieved using RPMI-1640 supplemented with 10% FCS. In comparison to the CSCs obtained with RPMI-1640, CSCs in the K-SFM expressed higher levels of Oct-4, ABCG2, Nanog and N-cadherin, and lower level of E-cadherin.</p><p><b>CONCLUSION</b>K-SFM is an optimal culture medium to maintain and to enrich breast CSCs.</p>